Francesco Perrone

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

Massimo Di Maïo, Ciro Gallo, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2015 · 478 citations · Full text

Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study

Paolo Maione, Francesco Perrone, Ciro Gallo et al. · Journal of Clinical Oncology · 2005 · 477 citations · Full text

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline

Massimo Di Maïo, Ethan Basch, Fabrice Denis et al. · Annals of Oncology · 2022 · 435 citations · Full text

Surgical Oncology, Medicine, Cancer Management +10

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

Chiara Carlomagno, Francesco Perrone, Ciro Gallo et al. · Journal of Clinical Oncology · 1996 · 409 citations

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros et al. · The Lancet Oncology · 2014 · 386 citations

Advanced Ovarian Cancer, Medicine, Metronomic Therapy +7